论文部分内容阅读
目的：评价枸椽酸莫沙必利对功能性消化不良（FD）的疗效及安全性。方法：60例FD患者随机分为两组，治疗组予以枸椽酸莫沙必利5mg，3次/d，治疗4周；对照组予以西沙必利5mg，3次/d，治疗4周。治疗前存在胃排空延迟患者，治疗后用不透X线小钡条法复查固体食物胃排空。结果：莫沙必利及西沙必利治疗4周均可显著改善FD患者早饱、上腹胀、上腹痛、暧气、反酸及烧心感等症状（与治疗前比P＜0．01）；莫沙必利对上述症状的有效率分别为59．09％、55．56％、81．82％、71．43％、100％及76．92％，西沙必利有效率分别为45．45％、73．33％、71．43％、82．61％、92．86％及66．67％，两组比较无显著差异（P＞0．05）。莫沙必利及西沙必利均可改善胃排空延迟患者胃排空率，前者对胃排空改善的有效率为88．24％，后者为83．33％，两组比较无显著差异（P＞0．05）。两组患者治疗后均无 QTC间期延长等不良反应。结论：枸椽酸莫沙必利是治疗 FD安全、有效的药物。
Objective: To evaluate the efficacy and safety of mosapride citrate in patients with functional dyspepsia (FD). Methods: Sixty FD patients were randomly divided into two groups. The treatment group was treated with mosapride citrate 5 mg three times a day for 4 weeks. The control group was given cisapride 5 mg three times a day for 4 weeks. Before treatment there was a delay in gastric emptying in patients after treatment with radiopaque barium review of solid food gastric emptying. Results: Both mosapride and cisapride treatment for 4 weeks could significantly improve symptoms such as early fullness, abdominal distention, upper abdominal pain, warm air, acid reflux and heartburn in FD patients (P <0.01 compared with those before treatment). The effective rates of mosapride on the above symptoms were 59.09%, 55.56%, 81.82%, 71.43%, 100% and 76.92%, respectively, and the effective rates of cisapride were 45.45 %, 73.33%, 71.43%, 82.61%, 92.86% and 66.67%, respectively. There was no significant difference between the two groups (P> 0.05). Mosapride and cisapride can improve gastric emptying rate in patients with delayed gastric emptying, the former effective rate of gastric emptying was 88.24%, the latter was 83.33%, there was no significant difference between the two groups (P> 0.05). No adverse reactions such as prolongation of QTC interval were found after treatment in both groups. Conclusion: Mosapride citrate is a safe and effective drug for the treatment of FD.